Plasma cell CD20 expression: primary aberrant expression or receptor up-regulation

被引：5

作者：

Ajaz, Bushra ^{[1
]}

Akhtar, Adnan ^{[1
]}

Chang, Chung-Che ^{[1
]}

Solh, Melhem ^{[1
]}

Tangonan, Kay ^{[1
]}

Khaled, Yasser ^{[1
]}

机构：

[1] Florida Hosp, Inst Canc, Orlando, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2014年 / 55卷 / 02期

关键词：

MULTIPLE-MYELOMA; RITUXIMAB; RESISTANCE; ANTIBODY; THERAPY; TRIAL;

D O I：

10.3109/10428194.2013.802782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：444 / 446

页数：3

共 13 条

[1]

Braylan RC, 2001, CYTOMETRY, V46, P23, DOI 10.1002/1097-0320(20010215)46:1<23::AID-CYTO1033>3.0.CO

[2]

2-Z

[3] Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma [J].

Chaidos, Aristeidis ;

Barnes, Chris P. ;

Cowan, Gillian ;

May, Philippa C. ;

Melo, Valeria ;

Hatjiharissi, Evdoxia ;

Papaioannou, Maria ;

Harrington, Heather ;

Doolittle, Helen ;

Terpos, Evangelos ;

Dimopoulos, Meletios ;

Abdalla, Saad ;

Yarranton, Helen ;

Naresh, Kikkeri ;

Foroni, Letizia ;

Reid, Alistair ;

Rahemtulla, Amin ;

Stumpf, Michael ;

Roberts, Irene ;

Karadimitris, Anastasios .

BLOOD, 2013, 121 (02) :318-328

[4] Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma [J].

Jakubowiak, Andrzej J. ;

Kendall, Tara ;

Al-Zoubi, Ammar ;

Khaled, Yasser ;

Mineishi, Shin ;

Ahmed, Asra ;

Campagnaro, Erica ;

Brozo, Christine ;

Braun, Thomas ;

Talpaz, Moshe ;

Kaminski, Mark S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5015-5022

[5] Anti-CD20 monoclonal antibody therapy in multiple myeloma [J].

Kapoor, Prashant ;

Greipp, Patricia T. ;

Morice, William G. ;

Rajkumar, S. Vincent ;

Witzig, Thomas E. ;

Greipp, Philip R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) :135-148

[6] Characterization of clonogenic multiple myeloma cells [J].

Matsui, W ;

Huff, CA ;

Wang, QJ ;

Malehorn, MT ;

Barber, J ;

Tanhehco, Y ;

Smith, BD ;

Civin, CI ;

Jones, RJ .

BLOOD, 2004, 103 (06) :2332-2336

[7] Rituximab in CD20 positive multiple myeloma [J].

Moreau, P. ;

Voillat, L. ;

Benboukher, L. ;

Mathiot, C. ;

Dumontet, C. ;

Robillard, N. ;

Herault, O. ;

Garnache, F. ;

Garand, R. ;

Varoqueaux, N. ;

Avet-Loiseau, H. ;

Harousseau, J. L. ;

Bataille, R. .

LEUKEMIA, 2007, 21 (04) :835-+

[8] The genetic architecture of multiple myeloma [J].

Morgan, Gareth J. ;

Walker, Brian A. ;

Davies, Faith E. .

NATURE REVIEWS CANCER, 2012, 12 (05) :335-348

[9] Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance [J].

Nair, Bijay ;

van Rhee, Frits ;

Shaughnessy, John D., Jr. ;

Anaissie, Elias ;

Szymonifka, Jackie ;

Hoering, Antje ;

Alsayed, Yazan ;

Waheed, Sarah ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2010, 115 (21) :4168-4173

[10] Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial [J].

Reeder, C. B. ;

Reece, D. E. ;

Kukreti, V. ;

Chen, C. ;

Trudel, S. ;

Hentz, J. ;

Noble, B. ;

Pirooz, N. A. ;

Spong, J. E. ;

Piza, J. G. ;

Zepeda, V. H. J. ;

Mikhael, J. R. ;

Leis, J. F. ;

Bergsagel, P. L. ;

Fonseca, R. ;

Stewart, A. K. .

LEUKEMIA, 2009, 23 (07) :1337-1341

← 1 2 →